Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, Jerald; Gray, Glenda; Vandebosch, An; Cárdenas, Vicky; Shukarev, Georgi; Grinsztejn, Beatriz; Goepfert, Paul; Truyers, Carla; Fennema, Hein; Spiessens, Bart; Offergeld, Kim; C. Scheper, Gert; L. Taylor, Kimberly; L. Robb, Merlin; J. Treanor, John; H. Barouch, Dan; J. Stoddard, Jeffrey; Ryser, Martin; Marovich, Mary; M. Neuzil, Kathleen; Corey, Lawrence; Cauwenberghs, Nancy; Tanner, Tamzin; Hardt, Karin; Ruiz‐Guiñazú, Javier; Le Gars, Mathieu; Schuitemaker, Hanneke; Van Hoof, Johan; Struyf, Frank; Douoguih, Macaya

doi:10.1056/nejmoa2101544

Public

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Published in New England Journal of Medicine • Apr 21, 2021

Authors:

Jerald Sadoff

Glenda Gray

An Vandebosch

Abstract

BACKGROUND: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. METHODS: viral particles) or placebo. The primary end ...

Subject

Medicine

Placebo

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!